SAN DIEGO—Sucroferric oxyhydroxide significantly decreases serum phosphorus levels and phosphate binder pill burden in peritoneal dialysis patients, according to study findings presented at Kidney Week.
In a retrospective study of 328 patients with high baseline phosphorus levels, a team led by Linda H. Ficociello, DSc, of Fresenius Medical Care North America in Waltham, Mass., observed a significant mean decline in phosphorus level from 6.92 mg/dL at baseline to 6.67 mg/dL after 3 months of treatment with sucroferric oxyhydroxide. In addition, results showed a significant 55% decrease in phosphate binder pills per day (from 8.4 to 3.8 pills), a significant 76% increase in the proportion of patients with serum phosphorus levels of 3.5–5.5 mg/dL, and a significant 21% increase in the proportion of patients with calcium × phosphorus product less than 55 mg2/dL2.
In a poster presentation, the investigators cited previous studies showing that a high pill burden among dialysis patients is associated with patient non-adherence to phosphate binder therapy and elevated serum phosphorus levels.
Study patients had an average age of 53 years and dialysis vintage of 3.9 years. At baseline, phosphate binder therapy consisted of sevelamer (55.8% of patients), calcium acetate (29%), calcium carbonate (10.7%), and combination therapy (4.5%).